| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2021 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 5 | NIH | 2/10/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $999,234 ) |
| | 2024 | 2024 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI155039 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | 000 | 4 | NIH | 4/23/2024 | $999,234 |
| | 2024 | 2022 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI157095 | Furopyrimidines as novel inhibitors of henipaviruses | 000 | 2 | NIH | 8/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $999,369 ) |
| | 2023 | 2023 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI155039 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | 000 | 3 | NIH | 4/27/2023 | $999,369 |
| | 2023 | 2021 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 5 | NIH | 7/21/2023 | $0 |
| | 2023 | 2021 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI155039 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | 001 | 1 | NIH | 6/20/2023 | $0 |
| | 2023 | 2020 | CHICAGO BIOSOLUTIONS INC | 2242 W HARRISON ST | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI145727 | Development of group 2 influenza A virus entry inhibitors | 000 | 2 | NIH | 6/9/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,299,036 ) |
| | 2022 | 2022 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI157095 | Furopyrimidines as novel inhibitors of henipaviruses | 000 | 2 | NIH | 2/14/2022 | $299,667 |
| | 2022 | 2022 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI155039 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | 000 | 2 | NIH | 5/5/2022 | $999,369 |
|
| Issue Date FY: 2021 ( Subtotal = $1,581,983 ) |
| | 2021 | 2021 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 5 | NIH | 7/14/2021 | $982,388 |
| | 2021 | 2021 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI155039 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | 000 | 1 | NIH | 4/1/2021 | $300,000 |
| | 2021 | 2021 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI157095 | Furopyrimidines as novel inhibitors of henipaviruses | 000 | 1 | NIH | 1/11/2021 | $299,595 |
|
| Issue Date FY: 2020 ( Subtotal = $1,261,659 ) |
| | 2020 | 2020 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI145727 | Development of group 2 influenza A virus entry inhibitors | 000 | 2 | NIH | 3/13/2020 | $299,999 |
| | 2020 | 2020 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 4 | NIH | 7/1/2020 | $961,660 |
| | 2020 | 2017 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI127031 | 4-Aminopiperidines as novel anti-influenza agents | 000 | 2 | NIH | 12/4/2019 | $0 |
| | 2020 | 2017 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 2 | NIH | 3/25/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,272,474 ) |
| | 2019 | 2019 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI145727 | Development of group 2 influenza A virus entry inhibitors | 000 | 1 | NIH | 3/29/2019 | $299,999 |
| | 2019 | 2019 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R42AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 3 | NIH | 8/16/2019 | $972,475 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
| | 2019 | 2016 | Chicago Biosolutions, Inc. | 2242 West Harrison Suite 201 | Chicago | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 04 | 1 | CDC | 9/30/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2016 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 11/15/2017 | $0 |
| | 2018 | 2016 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 11/15/2017 | $0 |
| | 2018 | 2016 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 11/15/2017 | $0 |
| | 2018 | 2016 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 11/15/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $516,781 ) |
| | 2017 | 2017 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI127031 | 4-Aminopiperidines as novel anti-influenza agents | 000 | 2 | NIH | 5/31/2017 | $127,703 |
| | 2017 | 2017 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI127031 | 4-Aminopiperidines as novel anti-influenza agents | 001 | 2 | NIH | 6/14/2017 | $25,480 |
| | 2017 | 2017 | CHICAGO BIOSOLUTIONS, INC. | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612-3515 | COOK | USA | R41AI126971 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents | 000 | 2 | NIH | 7/11/2017 | $363,598 |
|
| Issue Date FY: 2016 ( Subtotal = $831,514 ) (Continued on the next page) |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 8/25/2016 | $41,491 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 8/25/2016 | $29,292 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 000 | 1 | CDC | 8/25/2016 | $81,384 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 002 | 1 | CDC | 9/9/2016 | $72,833 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 002 | 1 | CDC | 9/9/2016 | $29,292 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 002 | 1 | CDC | 9/9/2016 | $41,491 |
| | 2016 | 2016 | CHICAGO BIOSOLUTIONS, INC | 2242 WEST HARRISON SUITE 201 | CHICAGO | IL | 60612 | COOK | USA | R43CK000495 | Furopyrroles as Novel anti-Ebola Agents | 002 | 1 | CDC | 9/9/2016 | $81,384 |
|
